You are here

Mitigation of Acute and Chronic Kidney Injuries by Systemic Infusion of Adipose-Derived Soluble Therapeutic Factor Concentrate

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41DK115317-01A1
Agency Tracking Number: R41DK115317
Amount: $238,130.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: 300
Solicitation Number: PA17-303
Solicitation Year: 2017
Award Year: 2018
Award Start Date (Proposal Award Date): 2018-09-20
Award End Date (Contract End Date): 2019-08-31
Small Business Information
11650 LANTERN RD STE 232
Fishers, IN 46038-3099
United States
DUNS: 078425194
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (317) 902-6630
Business Contact
Phone: (317) 919-8911
Research Institution
United States

 Nonprofit College or University

Acute kidney injuryAKIis a syndrome characterized by rapid loss of the kidneyandapos s excretory functionAKI is the
leading cause of nephrology consultation and results inmillion hospital admissions a yearThe socioeconomic
impact of AKI is significantresulting in $billion cost to the health care systemDespite the high rate of
incidence of AKIno therapy currently existsother than supportive careAlsoAKI occurs in up toof all
patients undergoing cardiac surgeryDespite advances in bypass techniques and intensive caremortality and
morbidity associated with AKI have not changed in the last decadeFurthermoreAKI represents a potential link
to chronic kidney diseaseMesenchymal stem cellMSCtherapies have shown promise in renal disease
modelshoweverthere are logistical barriers and potential safety concerns which will limit the usefulness of this
therapyWe and others have shown the therapeutic potential of MSC secretome in ischemia reperfusionacutekidney injury modelsHerewe propose to assess the therapeutic effect of NFxour lead therapeutic agentin the rat kidney ischemia reperfusion injury model when infused beforeimmediately afterorhours post
injury as well as to evaluate the therapeutic effect of NFxto prevent development of chronic kidney injury in
a rat model of high salt induced kidney failureAs a result of this Phase I study we will establish the optimal NFxdose and regiment of treatmentwhich then will be used for Phase II study NARRATIVE
Acute kidney injurya syndrome characterized by the rapid loss of the kidneyandapos s excretory functionis the leading
cause of nephrology consultationandmillion hospital admissions a yearresulting in health care costs of $billionand one of the major causes of development of chronic kidney diseaseUnfortunatelyAKI specific
interventions beyond supportive therapy are currently not availableWe propose to develop a therapy based on
therapeutic factors produced by stem cells that could potentially benefit the patients with acute kidney injury by
reducing the damage of the functional tissue and vasculature of the kidneys

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government